Point-of-Care HCV RNA Test Could Expedite Diagnosis, Treatment in High-Risk Settings

HCP Live October 11, 2024
Abigail Brooks, MA

Key Takeaways

• The Xpert HCV assay facilitates rapid HCV diagnosis in nonclinical settings, aiding high-risk populations like those under community supervision.
• FDA approval of the Xpert HCV test enables a faster test-and-treat approach, bypassing traditional multistep processes.
• Study limitations include single-site design and reliance on confirmatory testing, potentially affecting generalizability and causing delays.

New research is calling attention to the potential utility of a point-of-care hepatitis C virus (HCV) RNA assay (Xpert HCV) in a nontraditional, nonclinical setting for facilitating more rapid diagnosis and linkage to care among individuals under active community supervision.¹

Study results showed that the availability of a point-of-care HCV RNA assay for clinical use among individuals under active probation or parole would have enabled...

Today's Sponsors

Today's Sponsor